Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver-Reference-Cited by-同舟云学术

Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver

Published:2024 Issue: Volume: Page:
ISSN:2515-4184
Container-title:Molecular Omics
language:en
Short-container-title:Mol. Omics

Author:

Vasilogianni Areti-Maria¹²^ORCID,Alrubia Sarah¹³,El-Khateeb Eman¹⁴⁵^ORCID,Al-Majdoub Zubida M.¹^ORCID,Couto Narciso¹,Achour Brahim¹⁶,Rostami-Hodjegan Amin¹⁵,Barber Jill¹

Affiliation:

1. Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK

2. DMPK, Oncology R&D, AstraZeneca, Cambridge, UK

3. Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

4. Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt

5. Certara Inc (Simcyp Division), 1 Concourse Way, Sheffield, UK

6. Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA

Abstract

Two widely-used proteomic tools were compared, for the first time with precious healthy human liver samples from healthy volunteers, to form the basis of secure data-handling.

Funder

University of Manchester

Ministry of Education – Kingdom of Saudi Arabi

Merck KGaA

Publisher

Royal Society of Chemistry (RSC)

Subject

Genetics,Molecular Biology,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MO/D3MO00144J

Reference84 articles.

1. Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients

2. Significantly Decreased and More Variable Expression of Major CYPs and UGTs in Liver Microsomes Prepared from HBV-Positive Human Hepatocellular Carcinoma and Matched Pericarcinomatous Tissues Determined Using an Isotope Label-free UPLC-MS/MS Method

3. Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics

4. Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study

5. Proteomic Quantification of Human Blood–Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients